公开(公告)号：US20240191185A1

公开(公告)日：2024-06-13

申请号：US18283744

申请日：2022-03-25

Applicant: KANEKA CORPORATION

Inventor： Sho KAMBAYASHI ,  Yoshikazu KAWAI

IPC: C12N5/0735 ,  C12N5/074

CPC classification number: C12N5/0606 ,  C12N5/0696 ,  C12N2500/02

Abstract: The pluripotent stem cell culture environment is appropriately controlled to improve production efficiency, and to suppress cell death when passaging pluripotent stem cells from suspension culture. Pluripotent stem cells subjected to suspension culture in a perfusion mode under appropriate medium perfusion conditions are passaged in the subsequent culture step, thereby improving passage efficiency. By strictly controlling the amount of medium perfused in line with the progress of culture of pluripotent stem cells and/or adjusting the amount of carbon dioxide gas supplied in line with the progress of culture of pluripotent stem cells, culture efficiency and productivity can be remarkably improved.

公开(公告)号：US20240034998A1

公开(公告)日：2024-02-01

申请号：US18375035

申请日：2023-09-29

Applicant: KANEKA CORPORATION

Inventor： Terasu KAWASHIMA ,  Yoshikazu KAWAI ,  Sho KAMBAYASHI

IPC: C12N5/077

CPC classification number: C12N5/0657 ,  C12N2513/00 ,  C12N2521/00

Abstract: An object of the present invention is to easily obtain a large number of cardiomyocyte spheroids from cardiomyocytes separated into single cells. The present invention provides a method of producing a cardiomyocyte spheroid, the method comprising a step of culturing cardiomyocytes separated into single cells while stirring liquid in a container in which the cardiomyocytes are suspended, thereby causing aggregation of the cells.

公开(公告)号：US20230094568A1

公开(公告)日：2023-03-30

申请号：US17798947

申请日：2021-02-12

Applicant: KANEKA CORPORATION ,  RIKEN

Inventor： Kazuhiro TAKEUCHI ,  Masato IBUKI ,  Yohei HAYASHI ,  Mami TAKASAKI ,  Sho KAMBAYASHI ,  Yoshikazu KAWAI

IPC: C12N5/074

Abstract: Pluripotent stem cells are suspension-cultured with the undifferentiated state thereof maintained. In suspension culture of pluripotent stem cells, the undifferentiated state is maintained by the presence of a PKC inhibitor, especially, a PKCβ inhibitor, and a tankyrase inhibitor (TNKS inhibitor).